Spots Global Cancer Trial Database for Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma

Official Title: A Phase II Study Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma (PRORADGLIO Study)

Study ID: NCT04747145

Conditions

Glioblastoma

Interventions

Radiation

Concurrent Chemotherapy (Temozolomide)

Adjuvant Chemotherapy (Temozolomide)

Study Description

Brief Summary: The primary protocol objective is to assess the impact of substituting pulsed reduced dose radiotherapy (pRDR) for standard radiation therapy in the upfront treatment of glioblastoma (GBM) on disease progression.

Detailed Description: This is a single-arm, single-center phase 2 study designed to assess the efficacy of pulsed reduced dose-rate radiotherapy in the initial treatment of maximally safely resected glioblastoma. The primary endpoint will be progression-free survival at six months. Patients with pathologically confirmed GBM who are planned for six weeks of adjuvant chemoradiation followed by six to12 months of adjuvant chemotherapy will be screened and enrolled after surgery.